<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02945982</url>
  </required_header>
  <id_info>
    <org_study_id>SGHLC20161023004</org_study_id>
    <nct_id>NCT02945982</nct_id>
  </id_info>
  <brief_title>Treatment of Moderate and Severe Cirrhotic Portal Hypertension Due to HBV With Fuzheng Huayu and Entecavir</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Open-label, Multi-Center Study to Assess the Efficacy and Safety of Fuzheng Huayu Combined With Entecavir and Carvedilol in Moderate and Severe Cirrhotic Portal Hypertension Due to Hepatitis B Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ShuGuang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Longhua Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Public Health Clinical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ShuGuang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Portal hypertension is a common pathology in chronic liver disease, particularly in liver&#xD;
      cirrhosis. Hepatitis B Virus (HBV) is one of most etiologies of liver cirrhosis in China. The&#xD;
      basic reason for portal hypertension in HBV is the largely deposition of hepatic&#xD;
      extracellular matrixes which causes high pressure in liver vessels. One of the most common&#xD;
      symptoms of cirrhotic portal hypertension is gastroesophageal varices.The effective&#xD;
      inhibition of HBV can partially stop or reverse liver fibrosis in patients with chronic&#xD;
      Hepatitis and liver cirrhosis due to HBV and the anti-fibrotic strategy focusing on the&#xD;
      regulation of hepatic extracellular matrix may have a great benefit. Therefore, antivirals&#xD;
      therapy is also a basic treatment for low-grade cirrhotic portal hypertension. Fuzheng Huayu&#xD;
      has been found to enhance the degradation of collagens in fibrotic liver and have a good&#xD;
      action against liver fibrosis in patients with chronic hepatitis B. However, there are no&#xD;
      high quality clinical evidences which can demonstrate if the combination of anti-viral and&#xD;
      anti-fibrotic therapy can relieve the pressure of liver vessels and decline incidence rate&#xD;
      and bleeding rate of gastroesophageal varices.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to establish the safety and efficacy of the&#xD;
      combination of Entecavir and Fuzheng Huayu for reverse rate of gastroesophageal varices in&#xD;
      patients with Moderate and Severe cirrhotic portal hypertension due to hepatitis B virus.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 5, 2018</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of clinical events: Variceal hemorrhage, Ascites, Encephalopathy, etc</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Grading varices</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of liver cancer</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Noninvasive portal hypertension index</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">184</enrollment>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>Entecavir/Carvedilol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tablet with Entrcavir and Carvedilol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Entecavir/Carvedilol/ Fuzheng Huayu</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet with Entrcavir and Carvedilol+ Tablet with Fuzheng Huayu</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir+Carvedilol</intervention_name>
    <description>The subjects will be taking half a Carvedilol per day at first week and one Carvedilol per day from second week. At the same time,the subjects will be taking one Entecavir tablet per day for 96 weeks.</description>
    <arm_group_label>Entecavir/Carvedilol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir+Carvedilol+ Fuzheng Huayu</intervention_name>
    <description>The subjects will be taking half a Carvedilol tablet per day at first week and one Carvedilol tablets per day from second week. At the same time,the subjects will be taking one Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 96 weeks.</description>
    <arm_group_label>Entecavir/Carvedilol/ Fuzheng Huayu</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  More than 6 months history of serum positive HBsAg&#xD;
&#xD;
          -  Abdominal ultrasonogram or CT scan or liver-biopsy specimen indicates liver cirrhosis&#xD;
&#xD;
          -  Age 18-65&#xD;
&#xD;
          -  Child-Pugh&lt;7 (Stage A)&#xD;
&#xD;
          -  Without portal hypertension（Endoscopy indicates no signs of gastroesophageal varices.）&#xD;
&#xD;
          -  Moderate and Severe of portal hypertension（Endoscopy indicates signs of&#xD;
             gastroesophageal varices that is line shape without red wales or spots and less than&#xD;
             0.3cm of diameter.）&#xD;
&#xD;
          -  The patient or the patient's guardian agrees to participate the random controlled&#xD;
             trial and sign the Informed Consent Form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary Lamivudine, Adefovir dipivoxil and Entecavir resistance&#xD;
&#xD;
          -  Decompensated cirrhosis、The Child-Pugh score≥7&#xD;
&#xD;
          -  Low-grade Cirrhotic Portal Hypertension.&#xD;
&#xD;
          -  Severe grade of portal hypertension（Endoscopy indicates signs of gastroesophageal&#xD;
             varices that is catenulate/nodular shape with or without red wales or spots and more&#xD;
             than 1.0cm of diameter.）&#xD;
&#xD;
          -  Decompensated liver cirrhosis Liver cancer&#xD;
&#xD;
          -  Liver histology conforming to other chronic liver diseases, such as moderate or severe&#xD;
             non-alcoholic fatty liver disease(more than 1/3 steatosis in liver ), chronic&#xD;
             hepatitis C, chronic hepatitis D, autoimmune hepatitis, primary biliary cholangitis,&#xD;
             primary sclerosing cholangitis, inherited metabolic liver disease, drug or toxic&#xD;
             induced liver injury, parasitic infections, alcoholic liver disease.&#xD;
&#xD;
          -  Have psychiatric history or uncontrollable epilepsy patient.&#xD;
&#xD;
          -  Uncontrollable diabetic patient&#xD;
&#xD;
          -  History of hemoglobin disease (such as alpha- or beta-thalassemia, sickle cell&#xD;
             disease, spherocytosis) or patients with toxic or autoimmune hemolytic anemia.&#xD;
&#xD;
          -  Severe background disease like chronic respiratory failure, circulatory failure,&#xD;
             kidney failure etc.&#xD;
&#xD;
          -  In situ organ transplantation (such as liver, kidney, lung and heart) or bone marrow&#xD;
             transplantation and stem cell transplantation.&#xD;
&#xD;
          -  Immunocompromised patients: such as HIV infection or take immunosuppressor or&#xD;
             glucocorticoid (such as cyclosporin, azathioprine, adrenocortical hormone) within 3&#xD;
             months or chemotherapy drugs (such as cyclophosphamide, ammonia and cancer&#xD;
             chemotherapy) and radioactive therapy.&#xD;
&#xD;
          -  Gestation or lactation period women and women who plan to get pregnant during the&#xD;
             study period.&#xD;
&#xD;
          -  Patient who are allergy to the experimental drug.&#xD;
&#xD;
          -  Using history of anti-viral or anti-fibrosis drug within 6 months.&#xD;
&#xD;
          -  Patients who are participating other trials.&#xD;
&#xD;
          -  Other situation where PI thinks the patient should be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CHENGHAI LIU, PHD,MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ShuGuang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JING LV, MD</last_name>
    <phone>+86-21-20256521</phone>
    <email>liver125@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>hui Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Jiang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Lv</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 23, 2016</study_first_submitted>
  <study_first_submitted_qc>October 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2016</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>ShuGuang Hospital</investigator_affiliation>
    <investigator_full_name>Liu Chenghai</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Portal Hypertension</keyword>
  <keyword>Fuzheng Huayu</keyword>
  <keyword>Hepatitis B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

